Setting Sustainability Goals with Pierre Luzeau (DCAT 2023)
Pierre Luzeau, CEO of Seqens, discusses Seqen's commitment to sustainability and how one can work toward it within their own company.
As part of ongoing coverage of DCAT, the PharmTech editors touched base with Pierre Luzeau, CEO of Seqens. In in our discussion, Pierre discussed various aspects of sustainability, including:
- The extensive measures his company has put in place to committ to sustainability
- Underappreciated practices and techniques that contribute to sustainability
- Why sustainability will be so pivotal for biopharma companies over the course of the next ten years.
For more of our coverage on DCAT in 2023, viewers can visit this page.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
